Zeneca hands new drugs work to Lowe Fusion

Pharmaceutical giant Zeneca has hired Lowe Fusion Healthcare to develop PR programmes for two cancer drugs after it impressed the company with its work on Accolate, an anti-asthma drug launched in the UK last week.

Pharmaceutical giant Zeneca has hired Lowe Fusion Healthcare to

develop PR programmes for two cancer drugs after it impressed the

company with its work on Accolate, an anti-asthma drug launched in the

UK last week.



Lowe Fusion has won the contract to handle UK and international PR for

Tomudex, a colorectal cancer drug, and the UK account for Arimidex, a

breast cancer drug.



Neil Kendle, Lowe Fusion chairman, said the contracts did not specify an

end date and that Lowe Fusion is already discussing next year’s work

with Zeneca.



Duncan Burke, professional relations and PR manager at Zeneca, said the

quality of Lowe Fusion’s strategic thinking and day to day work over

several years on Accolate helped it win the other Zeneca work.



The UK accounts for Arimidex and Tomudex will involve media relations

work with the medical and consumer press, and also opinion leader

development.



This involves identifying key opinion formers, ensuring they know

Zeneca’s products and delivering their views on cancer treatments to

general and medical audiences.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.